<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04950049</url>
  </required_header>
  <id_info>
    <org_study_id>Zhangyonghai02</org_study_id>
    <nct_id>NCT04950049</nct_id>
  </id_info>
  <brief_title>The Effect of Dilution and Prolonged Injection Time on Dexamethasone-induced Perineal Irritation</brief_title>
  <official_title>The Effect of Dilution With Glucose and Prolonged Injection Time on Dexamethasone-induced Perineal Irritation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>General Hospital of Ningxia Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>General Hospital of Ningxia Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy of dilution with glucose and&#xD;
      prolonged injection time on dexamethasone 21-phosphate induced perineal irritation (include&#xD;
      pian and pruritus).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dexamethasone is a synthetic glucocorticoid, which may cause perineal irritation when given&#xD;
      intravenously. The major clinical manifestations are pruritus and painï¼Œand the incidence vary&#xD;
      between 38%-71%. Some patients undergo spontaneous remission, while others develop into&#xD;
      severe pain or pruritus. In clinical practice, dexamethasone is always diluted with glucose&#xD;
      in many cases, but diluted dexamethasone in relieving dexamethasone induced perineal&#xD;
      irritation has not been studied yet. The aim of this study was to investigate the efficacy of&#xD;
      dilution with glucose on dexamethasone induced perineal irritation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 15, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of dexamethasone-induced perineal irritation</measure>
    <time_frame>During the first 3 min period after the injection of dexamethasone</time_frame>
    <description>The investigators record the number of cases of dexamethasone-induced perineal irritation (pain or pruritus) and calculate the incidence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of perineal irritation</measure>
    <time_frame>After the injection of dexamethasone, up to 5 minutes</time_frame>
    <description>If perineal irritation occurs, the investigators will record its duration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The severity of perineal irritation</measure>
    <time_frame>After the injection of dexamethasone, up to 5 minutes</time_frame>
    <description>If perineal irritation occurs, the investigators will assess its severity by using Visual Analogue Scale (the minimum is 0 and the maximum is 10, and the higher scores mean a worse outcome)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Adverse Effect</condition>
  <arm_group>
    <arm_group_label>2 ml dexamethasone (5 mg/ml)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 patients receive 2 ml dexamethasone (5 mg/ml) , the injection time of dexamethasone was less than 2s.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 ml dexamethasone (2mg/ml)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 patients receive 5 ml dexamethasone (2mg/ml) diluted with 5% glucose, the injection time of dexamethasone was 30s.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 ml dexamethasone (1mg/ml)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 patients receive 10 ml dexamethasone (1mg/ml) diluted with 5% glucose, the injection time of dexamethasone was 30s.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20 ml dexamethasone (0.5mg/ml)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 patients receive 20 ml dexamethasone (0.5mg/ml) diluted with 5% glucose, the injection time of dexamethasone was 30s.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>receive 2ml dexamethasone (5mg/ml)</description>
    <arm_group_label>2 ml dexamethasone (5 mg/ml)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diluted dexamethasone 5ml</intervention_name>
    <description>receive 5ml dexamethasone (2mg/ml) diluted with 5% glucose</description>
    <arm_group_label>5 ml dexamethasone (2mg/ml)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diluted dexamethasone 10ml</intervention_name>
    <description>receive 10ml dexamethasone (1mg/ml) diluted with 5% glucose</description>
    <arm_group_label>10 ml dexamethasone (1mg/ml)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diluted dexamethasone 20ml</intervention_name>
    <description>receive 20ml dexamethasone (0.5mg/ml) diluted with 5% glucose</description>
    <arm_group_label>20 ml dexamethasone (0.5mg/ml)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 18-65 years&#xD;
&#xD;
          -  ASA physical status I-II&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  On regular use of analgesic&#xD;
&#xD;
          -  Contraindication or allergy to steroid or glucose&#xD;
&#xD;
          -  Drug or alcohol abuse&#xD;
&#xD;
          -  Diagnosed with paresthesia or mental diseases&#xD;
&#xD;
          -  Communication disorders&#xD;
&#xD;
          -  Pregnancy or nursing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yonghai Zhang</last_name>
    <role>Principal Investigator</role>
    <affiliation>General Hospital of Ningxia Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hanxiang Ma</last_name>
    <phone>+86-13519591508</phone>
    <email>mahanxiang@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yonghai Zhang</last_name>
    <phone>+86-15909508072</phone>
    <email>zhangyonghai826@aliyun.com</email>
  </overall_contact_backup>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 23, 2020</study_first_submitted>
  <study_first_submitted_qc>June 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2021</study_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dexamethasone 21-phosphate</keyword>
  <keyword>Pain</keyword>
  <keyword>Pruritus</keyword>
  <keyword>Glucose</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

